1. New Insights on Treatment Strategies for mCRC:

2. Introduction

3. ESMO Guidelines: Cytoreduction as a Decision Driver

4. First-Line Treatment has a "Crucial Mission"

5. Consistent OS Benefit of Attaining ETS in More Recent Phase 3 Studies With Targeted Agents

6. ETS Correlates With Post-Progression Survival

7. Characteristics to Tailor Up-Front Treatment

8. Evidenced-Based First-Line Options Today

9. First-Line Treatment of mCRC: Cytoreduction in Fit Patients

10. FOLFOXIRI + Cetuximab: MACBETH Efficacy Results

11. FOLFOXIRI + Panitumumab: VOLFI Trial -- ORR (Primary Endpoint)

12. TRIPLETE Study: Phase 3 Trial

13. FIRE 4.5 (AIO KRK-0116) Study: Phase 2 Trial

14. ESMO Primary Tumor Location Pooled Analysis

15. Meta-Analysis: Response Rate

16. FOLFOXIRI + Anti-EGFR mAb

17. ESMO Primary Tumor Location Pooled Analysis

18. Mutations in RAS Emerge During Anti-EGFR Treatment and Decline When Treatment Is Suspended

19. Rechallenge With Anti-EGFR Drugs

20. Ongoing Clinical Trials Evaluating Anti-EGFR Rechallenge in mCRC

21. Possible Uses of "Liquid Biopsy"

22. Predictive Role of ctDNA: The CRICKET Study

23. NGS for ctDNA Analysis From Liquid Biopsy?

24. Comprehensive ctDNA Genomic Analysis by NGS (Guardant360) After Anti-EGFR Treatment in mCRC (N = 193)

25. High Intrapatient Genomic Heterogeneity and Subclonality Limit Treatment: Sym004-05 Clinical Trial

26. What Is the Clinical Relevance of Low Frequency Mutations
What Is the Clinical Relevance of Low Frequency Mutations? TTD -- Platform Study

27. Treating Tumor Heterogeneity and Clonal Evolution

28. From Single Targeting to Multi-Targeting: Increasing Clinical Benefit in BRAF+ mCRC

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)